Market Cap : 7.41 B | Enterprise Value : 6.15 B | PE Ratio : | PB Ratio : 8.49 |
---|
NAS:IONS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:IONS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ionis Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2020 was $33.0 Mil. It means Ionis Pharmaceuticals's Accounts Payable & Accrued Expense increased by $33.0 Mil from Sep. 2020 to Dec. 2020 .
Ionis Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2020 was $-1.6 Mil. It means Ionis Pharmaceuticals's Accounts Payable & Accrued Expense declined by $1.6 Mil from Dec. 2019 to Dec. 2020 .
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.
Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2020 was 0.411 (Mar. 2020 ) + -15.35 (Jun. 2020 ) + -19.705 (Sep. 2020 ) + 33.034 (Dec. 2020 ) = $-1.6 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
No Headline